Q-omics provides the consensus-scored NLRP8 profile across patient tissues and cancer cell-line models. NLRP8 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, NLRP8 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, NLRP8 RNA expression shows 8,145 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, PRAD, and TGCT as cancer lineages where NLRP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRP8 survival associations across molecular data types. NLRP8 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRP8 RNA expression–survival associations across cancer types. High NLRP8 expression shows unfavorable associations in LUSC, OV, THCA, KIRC and BLCA, but favorable associations in BRCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LUSC as the clearest survival context for NLRP8 RNA expression.
This table summarizes NLRP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for NLRP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRP8 shows higher tumor expression in PRAD, LUAD and LIHC. The PRAD box plot shows higher NLRP8 RNA expression in tumor versus normal tissue (log2 FC = +0.528, t-test p < 0.001).
This table shows molecular features associated with NLRP8 in patient tissues and cancer cell lines. In patient samples, NLRP8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRP8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
